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Propranolol hydrochloride, a non-selective beta-adrenergic blocker, has been widely
used in the treatment of hypertension, angina pectoris, pheochromocytoma and cardiac
arrhythmias (1). Because of its relatively short plasma half-life, patients are routinely
asked to take propranolol hydrochloride in divided daily doses, once every 6 to 8 h. Such
frequent drug administration may reduce patient compliance and therapeutic efficacy
(2). In recent years, slow or sustained release formulations of propranolol hydrochloride
have become available with claims that these formulations maintain beta adrenoreceptor
blockade throughout a 24 h period and enable the drug to be given once daily (3).
The multilayered tablet concept has been long utilized to develop sustained release
formulations. Such a tablet has a fast releasing layer and may contain bi- or triple layers
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to sustain the drug release (4). The pharmacokinetic advantage relies on the fact that
drug release from fast releasing granules leads to a sudden rise in the blood concentra-
tion. However, the blood level is maintained at steady state as the drug is released from
the sustaining granules. Among the different polymers, Eudragit (5, 6) and ethylcellu-
lose (7–11) have been used successfully to obtain appropriate sustained release matrix
formulations of different materials. The present study aims at formulating bilayered tab-
lets of propranolol hydrochloride with a fast release layer using sodium starch glycolate




Propranolol hydrochloride was obtained as a gift sample from Natco Pharma, India.
Ethylcellulose (15 cP) was procured from Genuine Chemicals, India. Eudragit RLPO [poly
(ethyl acrylate, methyl methacrylate, trimethylaminoethyl-methacrylate chloride)(1:2:02)]
and Eudragit RSPO [poly(ethyl acrylate, methyl methacrylate, trimethylamino methyl
methacrylate chloride) (1:2:01)] were procured from S D Fine Chemicals, India. Starch
was obtained from Meghana Products, India, talc was procured from Swastik Pharma-
ceuticals, India, and magnesium stearate was procured from Nice Chemicals, India. Other
materials and solvents used were of analytical grade.
Preparation and characterization of bilayer tablets
The bilayer tablets of propranolol hydrochloride were prepared by the wet granula-
tion method. The drug and polymers for both fast release and sustaining layer were pas-
sed through a 180-µm sieve before their use in the formulation.
Formulation of the fast release layer. – The dose in the formulation for fast release was
25 mg, the maintenance dose or sustained dose (55 mg) of propranolol hydrochloride
was calculated as per the reported method (12, 13). The fast release granules were pre-
pared by wet granulation technique by blending propranolol hydrochloride uniformly
with sodium starch glycolate using starch paste (10% m/m) as binder as per the formulae
given in Table I. The cohesive mass obtained was passed through a 1000 µm sieve, dried
at 60 °C for 1 h to give a moisture content of 4–6%, determined on an IR moisture bal-
ance (Macro Scientific Works, India). The granules were again passed through a 1000-µm
screen to break up agglomerates. The granules were mixed with talc and magnesium
sterate.
Formulation of the sustained release layer. – The sustaining granules were formulated
by the wet granulation technique, mixing propranolol hydrochloride uniformly with Eu-
dragit RLPO, Eudragit RSPO or ethylcellulose. Lactose was mixed with the above drug
and polymer mixture. Starch paste (10% m/m) was used as binder as per the formulae
given in Table II. The sustaining granules were also subjected to similar processing steps
as the fast releasing granules.
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Characterization of granules. – Prior to compression, granules were evaluated for their
characteristic parameters, such as tapped density, Carr’s index and angle of repose (15).
Carr’s compressibility index was calculated from the bulk and tapped densities (14)
using a digital tap density apparatus (Electrolab Ltd, India).
Compression of bilayer tablet. – The quantity of granules for the sustained release lay-
er was compressed lightly using a single punch-tableting machine (Cadmach Machinery
Co Pvt. Ltd., India) equipped with 6.5-mm round, flat and plain punches. Over this com-
pressed layer, the required quantity of the fast release layer was placed and compressed
to obtain hardness in the range of 5–7 kg cm–2 to form a bilayer matrix tablet.
Physical tests for the bilayer tablets. – Standard physical tests for the bilayer matrix
tablets were performed (16) and average values were calculated. Mass variation was de-
termined by weighing 20 tablets individually, the average mass was calculated and the
percent variation of each tablet was calculated. Hardness was determined by taking 6
tablets from each formulation using a Monsanto hardness tester (Electrolab Pvt. Ltd., In-
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Table I. Formulation of the fast release layer
Ingredient Quantity for a single tablet (mg)
Propranolol hydrochloride
Sodium starch glycolate








Table II. Formulation of the sustained release layer
Ingredient







Eudragit RSPO Eudragit RLPO
1:0.5 1:1 1:1.5 1:0.5 1:1 1:1.5
Propranolol
hydrochloride
55 55 55 55 55 55 55 55 55
Ethyl cellulose 27.5 55 82.5 – – – – – –
Eudragit RSPO – – – 27.5 55 82.5 – – –
Eudragit RLPO – – – – – – 27.5 55 82.5
Lactose 64.5 37 9.5 64.5 37 9.5 64.5 37 9.5
Starch paste
(10%)
14 14 14 14 14 14 14 14 14
Talc 2 2 2 2 2 2 2 2 2
Magnesium
stearate
1 1 1 1 1 1 1 1 1
dia) and the average of pressure (kg cm–2) applied for crushing the tablet was determin-
ed. Friability was determined by first weighing 10 tablets after dusting and placing them
in a friability tester (Electrolab Pvt. Ltd., India), which was rotated for 4 min at 25 rpm.
After dusting, the total remaining mass of the tablets was recorded and the percent fria-
bility was calculated.
Drug content uniformity. – Ten tablets were finely powdered and an amount equiva-
lent to 40 mg of propranolol hydrochloride was accurately weighed and transferred to a
100 mL volumetric flask, then 70 mL of methanol was added. The flask was shaken for
10 min. Finally, the volume was made up to the mark with methanol. The mixture was
then filtered and 1 mL of the filtrate was suitably diluted with methanol to obtain a solu-
tion containing about 40 µg mL–1 of propranolol hydrochloride and analyzed for pro-
pranolol hydrochloride content (17) at 290 nm using a double beam UV/Visible spec-
trophotometer (Elico Ind Ltd, India) and methanol as blank.
In vitro dissolution
Release of propranolol hydrochloride was determined using a USP 24 (17) six stage
dissolution rate test apparatus 1 (Labindia Instruments Pvt. Ltd, India) at 50 rpm. The
dissolution was studied using 900 mL of simulated gastric fluid (without enzyme, pH
1.2) for the first 2 h and followed by simulated intestinal fluid (without enzyme, pH 7.2)
for the remaining hours (17). The temperature was maintained at 37 ± 0.2 °C. The sam-
ple (5 mL) was withdrawn at different time intervals, i.e. 5, 15, 30, 60, 120, 180, 240, 300,
360, 480, 600 and 720 min, filtered through Whatman filter paper (Auroco Pvt Ltd, Thai-
land) and replaced by an equal volume of dissolution medium. Samples were suitably
diluted and analyzed for propranolol hydrochloride content at 290 nm.
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Table III. In-vitro dissolution kinetics of propranolol hydrochloride
Formulation
Drug release kinetics (R) Peppas release
exponent (n)Zero-order First-order Higuchi type
RSPO 1:0.5 0.984 0.969 0.993 0.745
RSPO 1:1 0.965 0.964 0.994 0.672
RSPO 1:1.5 0.979 0.952 0.988 0.610
RLPO 1:0.5 0.991 0.964 0.997 0.718
RLPO 1:1 0.959 0.939 0.994 0.649
RLPO 1:1.5 0.979 0.952 0.988 0.604
EC 1:0.5 0.983 0.969 0.995 0.673
EC 1:1 0.967 0.945 0.991 0.585
EC 1:1.5 0.977 0.963 0.990 0.589
Kinetic analysis of dissolution data
The rate and mechanism of release of propranolol hydrochloride from the prepared
bilayer tablets were analyzed by fitting the dissolution data into the zero-order equation
(18):
Q = k0t
where Q is the amount of drug released at time t, and k0 is the release rate constant, fit-
ted to the first order equation (19):
ln (100–Q) = ln 100 – k1t
where k1 is the release rate constant. The dissolution data was fitted to the Higuchi’s
equation (20)
Q = k2 t1/2
where k2 is the diffusion rate constant.
The dissolution data was also fitted to the well known equation (Korsmeyer equa-
tion), which is often used to describe the drug release behavior from polymeric systems
(21):
log (Mt/M¥) = log k + n log t
where Mt is the amount of drug released at time t, M¥ is the amount of drug release after
infinite time, k is a release rate constant incorporating structural and geometric charac-
teristics of the tablet and n is the diffusional exponent indicative of the mechanism of
drug release.
FT-IR study
Infrared spectrum was taken (FT-IR, Spectrum RX 1, Perkin Elmer Ltd, Swizerland)
by scanning the sample in potassium bromide discs. The samples of pure drug and
granules containing different polymers were scanned individually.
Statistical analysis
In vitro release data of propranolol hydrochloride from bilayer tablets of optimized
formulations were subjected to the analysis of variance (ANOVA) at two different time
intervals, 15 min and 12 h.
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RESULTS AND DISCUSSION
The prepared bilayer tablets were evaluated for various physical properties. The
bulk densities for the granules of various formulations ranged between 0.87 ± 0.14 and
2.42 ± 0.42 g mL–1, as determined by the tap method. This value of bulk density indi-
cates of good packing character. The compressibility index (CI) for all the formulations
was found to be below 15%, indicating desirable flow properties (14). The flow proper-
ties of granules were further analyzed by determining the angle of repose for all gran-
ules; it ranged between 21.32 ± 0.58 to 25.03 ± 0.23°. The value indicates good flow prop-
erty (15) of granules with Eudragit RLPO, Eudragit RSPO and ethylcellulose as matrix
material.
All the batches of tablets were produced under similar conditions to avoid process-
ing variables. Mass of the bilayer tablets was 201 ± 12 mg, hardness was 5.2 ± 1.2 kg
cm–2 and thickness was 2.9 ± 0.1 mm. The percentage friability of all the formulations
was 0.5 ± 0.3%. Values of the hardness test and percent friability indicate good handling
properties of the prepared bilayer tablets. The drug content uniformity in the bilayer
matrix tablets was 96.5 ± 4.9%.
The FT-IR spectrum of propranolol hydrochloride, shown in Fig. 1, revealed the
presence of peaks at 2965.1 cm–1 due to the presence of a secondary amine group, peaks
at 3283.7 cm–1 due to the hydroxyl group (secondary), the aryl alkyl ether displayed a
stretching band at 1268 cm–1 and the peak at 797.9 cm–1 was due to a-substituted naph-
thalene. The FT-IR spectra of propranolol hydrochloride granules containing different
types of polymer showed a broadening of peaks at 3283 cm–1 frequency due to extensive
hydrogen bonding. Major frequencies of functional groups of pure drug remain intact in
granules containing different polymers; hence, there is no major interaction between the
drug and polymers used in the study.
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Fig. 1. FT-IR spectra of pure propranolol hydrochloride (a) and propranolol hydrochloride
granules containing different polymers: ethylcellulose (b), Eudragit RSPO (c), and Eudragit
RLPO (d).
The release of propranolol hydrochloride from the prepared formulations was ana-
lyzed by plotting the cumulative percent drug released vs. time as shown in Figs. 2a–c.
Simple visual observation of the plot shows an initial burst effect. From all the formula-
tions, over 30% of the propranolol hydrochloride was released within the first 15 min of
the dissolution study. This initial high amount of propranolol hydrochloride release can
be attributed the immediate release layer of the formulation. Further release of propra-
nolol hydrochloride was studied for 12 h.
Ethylcellulose has been used as release retardant polymer in controlled release dos-
age forms (8, 22, 23). EC reduces the drug release due to a reduction in the penetration of
the solvent molecules into the system because of the hydrophobic nature of ethylcellu-
lose present on the surface of the tablet, i.e. the rate of release is controlled by the perme-
ability of matrix structure (24). As the proportion of ethylcellulose increase, the release
process of propranolol hydrochloride decreares (Fig. 2a). Fig. 2a shows that formulation
EC 1:0.5 could not sustain the release beyond 7 h whereas formulations EC 1:1 and EC
1:1.5 showed the desired release profile over the test period of 12 h. Therefore, formula-
tion EC 1:1 was selected as the optimized formulation keeping in view the minimum
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Fig. 2. Cumulative propranolol hydrochlo-
ride released vs. time (mean ± SD, n = 3)




amount of ethylcellulose required to sustain the release for a period of 12 h. In this se-
lected formulation, the calculated regression coefficients for Higuchi, zero order and
first order models were 0.991, 0.967 and 0.945, respectively. Therefore, the release seems
to fit the Higuchi model (Fig. 3). To explore the release pattern, results of the in vitro dis-
solution data were fitted to the Korsmeyer and Peppas equation (25), which character-
izes the transport mechanism. The value of release exponent (n) for the optimized for-
mulation EC 1:1 was 0.585, indicating release governed by non-Fickian diffusion (Fig. 4).
Similarly, formulations containing Eudragit RSPO (RSPO 1:0.5 and RSPO 1:1) and
Eudragit RLPO (RLPO 1:0.5 and RLPO 1:1) were unable to sustain the release of drug for
the desired period of 12 h (Fig. 2b,c). However, the formulation RSPO 1:1.5 and RLPO
1:1.5 could sustain the release for 12 h. Hence, these two were selected as optimized for-
mulations. The calculated regression coefficients for Higuchi, zero order and first order
models for the last two were 0.988, 0.979 and 0.952, and 0.988, 0.979 and 0.952, respec-
tively. Therefore, the release seems to fit the Higuchi model (Fig. 3). The Korsmeyer and
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Fig. 3. Higuchi plot for cumulative
percent propranolol hydrochloride re-
leased vs. square root of time (mean
± SD, n = 3).
Fig. 4. Koresmeyer and Peppas plot
of log of propranolol hydrochloride
released vs. log of time (mean ± SD,
n = 3).
Peppas release exponent (n) for formulation RSPO 1:1.5 was 0.610 and for RLPO 1:1.5
0.604, indicating release governed by non-Fickian diffusion (Fig. 4). The drug release
from formulation RSPO 1:1.5 was less compared to RLPO 1:1.5, because Eudragit RLPO
tends to swell more than Eudragit RSPO in aqueous medium (26, 27). Also, Eudragit
RLPO is more permeable to aqueous medium than Eudragit RSPO (28).
All the formulations prepared with ethycellulose, Eudragit RSPO and Eudragit RLPO
predominantly followed the Higuchi model and non-Fickian diffusion after the initial
burst release. In all the three polymers, permeability to water was the common rate con-
trolling factor.
Analysis of variance (ANOVA) showed no significant difference in the amount of
drug released after 15 min from optimized formulations EC 1:1, RSPO 1:1.5 and RLPO
1:1.5; however, significant differences (p < 0.05) were observed for the amount of drug
released after 12 h from the same formulations.
CONCLUSIONS
The present research was carried out to develop a bilayer tablet of propranolol hy-
drochloride using superdisintegrant sodium starch glycolate for the fast release layer
and ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining layer. Bilayer
tablets showed an initial burst effect to provide the loading dose of the drug, followed
by sustained release for 12 h, indicating a promising potential of the propranolol hydro-
chloride bilayer tablet as an alternative to the conventional dosage form.
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S A @ E T A K
Razvoj i vrednovanje dvoslojnih tableta propranolol hidroklorida
CHINAM NIRANJAN PATRA, ARETHI BHARANI KUMAR, HEMANT KUMAR PANDIT,
SATYA PRAKASH SINGH i MEDURI VIMALA DEVI
U radu je opisan razvoj dvoslojnih tableta propranolol hidroklorida, koriste}i superdez-
integrator {krob glikolat natrij u sloju za brzo osloba|anje i polimere koji se ne mije{aju s
vodom (etilceluloza, Eudragit RLPO i Eudragit RSPO) u sloju za usporeno osloba|anje. In
vitro osloba|anje pra}eno je u USP aparatu I te je uo~eno po~etno naglo osloba|anje lje-
kovite tvari iza kojeg slijedi polagano osloba|anje tijekom 12 sati. In vitro kinetika oslo-
ba|anja prati Higouchijev model, dok mehanizam kontroliranog osloba|anja ne slijedi
Fickov zakon poslije po~etnog naglog osloba|anja. FT-IR studije ukazuju da nema inter-
akcije izme|u ljekovite tvari i polimera upotrebljenih u oblikovanju. Statisti~ka analiza
(ANOVA) nije pokazala zna~ajne razlike u kumulativnoj koli~ini oslobo|enog lijeka iz
optimiranih formulacija poslije 15 minuta, ali polije 12 h jo{ se ta koli~ina zna~ajno raz-
likovala (p < 0.05).
Klju~ne rije~i: propranolol hidroklorid, dvoslojne tablete, {krob glikolat natrij, polimeri koji se ne
mije{aju s vodom, statisti~ka analiza
P.G. Department of Pharmaceutics, College of Pharmaceutical Sciences, Berhampur-760002, Orissa, India
489
Ch. Niranjan Patra et al.: Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride, Acta Pharm. 57
(2007) 479–489.
